- Details
- Ali Khaki and Petros Grivas come together to discuss a study Ali Khaki presented at the 2020 ASCO meeting, on the cost-effectiveness of atezolizumab added to first-line platinum chemotherapy for Advanced Urothelial Cancer. He with Dr. Grivas provides further insight into how this treatment plan was assessed, while also giving context regarding how cost-effectiveness is measured in cancer patients....
|
- Details
- Bishoy Faltas joins Alicia Morgans to discuss the cutting edge aspects of his research on urothelial cancer. Dr. Faltas shares information on the CLONEVO Trial and his team’s initial efforts on integrating machine learning and artificial intelligence in the care of bladder cancer patients. Biographies: Bishoy M. Faltas, MD, Director of Bladder Cancer Research, Englander Institute for Precision Med...
|
- Details
- The current standard of care for patients with localized muscle-invasive bladder cancer involves neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy. Unfortunately, even with chemotherapy and surgery, cancer recurrence is common, with a 5-year survival rate of 50—60%. Thus, additional strategies are necessary to help patients achieve long term survival. Thomas Powles and Matthe...
|
- Details
- The phase III JAVELIN Bladder 100 trial was the first urothelial carcinoma plenary session at an ASCO annual meeting in the meeting's history and Thomas Powles lead principal investigator on the trial along with Matthew Galsky join Alicia Morgans sharing results of this trial. This was a maintenance trial where first-line treatment with avelumab extended the survival over best supportive care (BSC...
|
- Details
- Srikala (Kala) Sridhar joins Alicia Morgans to discuss the recent developments in urothelial cancer of the bladder and upper tract. The two discuss controversial issues in urothelial carcinoma from the American Joint Committee on Cancer (AJCC) staging to chemotherapy in upper tract disease, to bladder sparing recent clinical trial findings, and the impact of those trials on clinical practice treat...
|
- Details
- Andrea Necchi, a medical oncologist and Ewan Gibb a researcher at Decipher Biosciences joins Alicia Morgans as they discuss new findings related to bladder cancer and the impact of molecular subtyping and immune infiltration on pathological response and outcome following neoadjuvant pembrolizumab in muscle-invasive bladder cancer, an area of unmet need in bladder cancer. The trio cover patient sel...
|
- Details
- Cora Sternberg joins Alicia Morgans at ASCO GU 2020 and discusses the significant advancements in the treatment of advanced bladder cancer looking back over the last 30 years. MVAC was regulatory approved as the first line treatment in metastatic bladder cancer thirty years ago. Cora discusses the recent progress that is offering significant improvements in the overall survival for those patients...
|
- Details
- Alicia Morgans is joined by Peter O’Donnell and Jonathan Rosenberg to discuss enfortumab vedotin (EV). This offers a new mechanism of action and is the first antibody-drug conjugate (ADC). This represents a targeted therapy and was studied in metastatic urothelial carcinoma. In reviewing the clinical data and side effects of the drug, the three clinicians highlight the effectiveness and tolerabili...
|
- Details
- Joining Alicia Morgans is Matt Galsky to discuss the biggest updates in bladder cancer clinical trials. Building off of his overview of IMvigor130, KEYNOTE-361, and JAVELIN Bladder 100, Dr. Galsky provides insight on how he incorporates clinical data into his everyday practice and the direction he believes the field is moving towards in the future. Biographies: Matthew Galsky, MD Director of Genit...
|
- Details
- Ashish Kamat sits down with Petros Grivas to discuss the recent advances and clinical trials in second and third-line therapies in metastatic urothelial cancer. Biographies: Petros Grivas, MD, PhD , Associate Professor, Clinical Director of Genitourinary Cancers Program, University of Washington, Associate Member, Clinical Research Division, Fred Hutchinson Cancer Research Center Ashish Kamat, MD,...
|
